Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Relovair Data Raises Respiratory Stakes For GSK And Theravance

Executive Summary

Mixed Phase III data results on GSK/Theravance’s once-daily follow-up to Advair raises the regulatory and commercial stakes for the drug, a crucial pipeline product for both companies

You may also be interested in...



COPD Market Snapshot: New Products, Limited Differentiation

New drugs are hitting the COPD market, but largely offer incremental benefit over gold standards Advair and Spiriva. Given the modest efficacy improvement and increasingly price sensitive patients and payers, new higher-priced products may find the commercial market a challenge.

For Theravance, A Big Year Gets Off To A Strong Start

Theravance could soon have its first substantial revenue generator on the market, the COPD therapy Breo Ellipta partnered with GlaxoSmithKline. The launch of Breo is just one of several catalysts expected to unfold for the biotech in 2013.

FDA Panel Will Weigh Mixed Efficacy Data For GSK’s Breo Ellipta In COPD

Agency says data supporting the relative contribution of the combination drug’s corticosteroid component, fluticasone, are “less robust” than data supporting the bronchodilatory effects of the long-acting beta-agonist component, vilanterol.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS054110

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel